BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 ...

Following recommendations by the World Health Organization (WHO), the United Nations Commission on Narcotic Drugs (CND) has decided to place five new psychoactive substances and one medicine under ...

The firm refinanced leveraged loan due to be repaid this year Boost from ADHD drug shortage may be coming to an end: S&P Alvogen Pharma US Inc. has arranged a new private loan led by Centerbridge ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

The U.S. and its major trading partners have agreed to reciprocal tariff elimination for pharmaceutical products and chemicals used in drug production for the past 30 years, according to the U.S ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $300.00. The company’s shares closed yesterday at $245.20.

Pakistan Single Window (PSW) CEO Syed Aftab Haider has said that digitalisation of regulatory processes will simplify compliance requirement and help pharmaceutical firms to reduce the time and ...

Gland Pharma Ltd on Tuesday (February 25) announced that America's drug regulatory watchdog has completed a crucial inspection of its Andhra Pradesh facility. In a regulatory filing, Gland Pharma said ...

Its time for Indian pharma companies to look beyond the U.S. market as the Trump administration has threatened to impose 25% tariff on pharmaceutical imports. This move would disrupt India’s ...